Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Carbon Coated Zirconium Beads In Beta-glucan Gel And Bovine Glutaraldehyde Cross-linked Collagen Injections For Intrinsic Sphincter Deficiency: Continence And Satisfaction After Extended Followup.

K. Chrouser, F. Fick, A. Goel, N. B. Itano, S. Sweat, D. Lightner
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
PURPOSE The durability of Durasphere (Carbon Medical Technologies, Saint Paul, Minnesota), used to treat stress urinary incontinence, has not been shown beyond 12 months of followup. Women treated with Durasphere and Contigen (Bard, Inc., Covington, Georgia) at 1 institution between 1996 and 2000 were compared to determine patient satisfaction and urinary continence after extended followup. MATERIALS AND METHODS Between April 1996 and September 2000, 56 women were treated with Durasphere at this institution, of whom 43 were available for extended followup. Aged matched patients treated with Contigen were analyzed for comparison. Patient satisfaction and continence at last followup were subjectively assessed via telephone interview. Survival methods (Kaplan-Meier and Cox proportional hazards model) were used to analyze time to failure as a function of treatment group and other potential predictors. RESULTS Treatment groups (Contigen and Durasphere) were similar with respect to all baseline factors. Treatment was initially effective in 63% of Durasphere and Contigen cases (p = 1.0). At 24 and 36 months Durasphere remained effective in 33% and 21% of patients compared with 19% and 9% for Contigen, respectively. At last followup only 9 patients (21%) treated with Durasphere and 2 (5%) treated with Contigen (median followup 51 and 62 months, respectively) claimed that treatment was still effective. After controlling for differences in followup time there was no significant difference in time to failure between the treatment groups (p = 0.25). A third of patients in each group believed that treatment was a success. CONCLUSIONS Neither Contigen nor Durasphere provides durable improvement in continence. Despite this outcome a third of patients in the 2 groups were satisfied with the treatment outcome.
This paper references

This paper is referenced by
Nonsurgical Outpatient Therapies for the Management of Female Stress Urinary Incontinence: Long-Term Effectiveness and Durability
G. Davila (2011)
Tension-free vaginal tape after failed cystoscopic transurethral injections for stress urinary incontinence
D. Altman (2009)
Minimally Invasive Therapies for Female Stress Urinary Incontinence: the Current Status of Bioinjectables/New Devices (Adjustable Continence Therapy, Urethral Submucosal Collagen Denaturation by Radiofrequency)
S. Crivellaro (2009)
Regenerative Therapy for Stress Urinary Incontinence
R. Jankowski (2008)
Stress Urinary Incontinence Secondary to Intrinsic Sphincteric Deficiency
R. W. Frederick (2006)
Long-term evaluation of bulking agents for the treatment of fecal incontinence: clinical outcomes and ultrasound evidence
F. Guerra (2014)
Role of three-dimensional ultrasound in assessment of women undergoing urethral bulking agent therapy
C. Poon (2004)
Sling failures: What’s next?
H. Scarpero (2004)
Combined urinary and faecal incontinence
D. Kapoor (2004)
Intrinsic sphincter deficiency (ISD)
C. Dowling (2004)
Long-term effects of dextranomer endoscopic injections for treatment of urinary incontinence: an update of a prospective study of 31 patients.
H. Lottmann (2006)
Case reports: periurethral bulking agents and presumed urethral diverticula
Disha Kumar (2011)
Update on Urethral Bulking Agents for Female Stress Urinary Incontinence due to Intrinsic Sphincter Deficiency. J Urol Res 1(2): 1009.
G. Ghoniem (2014)
Combined trans- and periurethral injections of bulking agents for the treatment of intrinsic sphincter deficiency
E. Sokol (2007)
Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results.
G. Ghoniem (2010)
An evidence-based approach to the evaluation and management of stress incontinence in women
Jason P. Gilleran (2005)
New treatments for incontinence.
Lara S. MacLachlan (2015)
Current Status of Tissue Engineering in Stress Urinary Incontinence
H. Wang (2011)
Surgery Insight: surgical management of postprostatectomy incontinence—the artificial urinary sphincter and male sling
C. Comiter (2007)
Skeletal myogenic differentiation of urine-derived stem cells and angiogenesis using microbeads loaded with growth factors.
Guihua Liu (2013)
Surgery Insight: management of failed sling surgery for female stress urinary incontinence
C. Comiter (2006)
Stress incontinence injection therapy: what is best for our patients?
C. Chapple (2005)
Stem cell therapy for stress urinary incontinence
Dmitriy Nikolavsky (2010)
Durasphere® EXP: a non-biodegradable agent for treatment of primary Vesico-Ureteral reflux in children
U. Ozkuvanci (2018)
Injectables for the treatment of stress urinary incontinence: current use and future perspectives
P. Perimenis (2006)
Management of Recurrent or Persistent Stress Urinary Incontinence after Mid‐urethral Sling
Ji-Yeon Han (2012)
Long‐term results of perianal silicone injection for faecal incontinence
Y. Maeda (2007)
Development of cellular therapy for the treatment of stress urinary incontinence
H. Wang (2011)
Injectable Bulking Agents
C. Vaizey (2007)
Not all that bulges is vaginal prolapse.
Dee E. Fenner (2011)
Bioinjectables for Stress Urinary Incontinence
R. Dobbs (2018)
Title Update on Urethral Bulking Agents for Female Stress Urinary Incontinence due to Intrinsic Sphincter Deficiency
G. Ghoniem (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar